echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Two new hepatitis B projects of guangshengtang failed to be approved

    Two new hepatitis B projects of guangshengtang failed to be approved

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In April 2014, China Securities Regulatory Commission disclosed the prospectus of Fujian guangshengtang Pharmaceutical Co., Ltd

    (hereinafter referred to as "guangshengtang")

    This enterprise, which specializes in the use of hepatitis B drugs, has three first-line drugs in the field of hepatitis B treatment

    However, the two new drugs (entecavir dispersible tablets and pantoprazole sodium enteric coated capsules) mentioned in the prospectus are not approved now

    Just last month, two failed notices of new drug approval were sent to guangshengtang from the national drug examination center, one of which is of great significance to the company's deep work in the field of hepatitis B drug use, and many enterprises have been approved

    Industry insiders pointed out that the failure of approval of mature varieties exposed the weakness of guangshengtang's R & D ability and government affairs ability

    Under the background of the aging of existing varieties and the weakening of competitiveness, it is very important for the company to succeed in applying for new varieties

    Two new drugs to be approved have failed

    Guangshengtang mentioned in the prospectus that entecavir dispersible tablets and pantoprazole sodium enteric coated capsules are in the period of approval

    In April this year, guangshengtang has received the review and approval documents of entecavir dispersible tablets and pantoprazole sodium enteric coated capsules

    The result is "it is recommended to maintain the original approval conclusion", which means that the approval is failed

    Industry insiders pointed out that these two new drugs are mature varieties produced by many pharmaceutical companies, and the technical threshold is not high

    This is not guangshengtang's first failure

    As early as June 2013, guangshengtang failed in the approval of the above two new drugs

    Soon after, guangshengtang applied for review of pantoprazole sodium enteric coated capsules and entecavir dispersible tablets, the specific stages of application were production and clinical

    In the prospectus, guangshengtang only mentioned that the review of pantoprazole sodium enteric coated capsules was more likely to fail, but the risk of entecavir dispersible tablets, a more core variety, was hidden later

    As an enterprise focusing on hepatitis B drugs, entecavir dispersible tablets are the mainstream varieties and dosage forms in the field of hepatitis B treatment

    Compared with the current main variety of the company - capsule, the absorption is faster, the price is higher, and the competition pattern is better

    Pharmaceutical companies have rich dosage forms, and will have more advantages in participating in provincial bidding

    For the failure of the approval of the two new drugs again, guangshengtang told the big wisdom News Agency: "the company has always adhered to a scientific and rigorous attitude to carry out the research and development of new drugs

    As for the specific reasons for the failure of the two drugs, it is recommended to consult the relevant government departments

    The company has made a prompt on R & D risk "

    "There are many reasons why the application for new drugs has been rejected," a researcher from a pharmaceutical company told the big smart news agency

    But if several enterprises have been approved for production, the ability of the dead pharmaceutical enterprises in R & D and government affairs is questionable

    "

    It is worth mentioning that as a small pharmaceutical enterprise, guangshengtang's R & D investment is not stingy

    From 2011 to 2013, guangshengtang's R & D investment was 9.9152 million yuan, 14.9658 million yuan and 15.555 million yuan, respectively, accounting for 9.44%, 11.90% and 8.73% of the current operating revenue, higher than the industry average of 5% to 7% of the R & D investment

    In addition, tenofovir dipivoxil maleate capsule and tenofovir dipivoxil maleate have entered the status of application for production approval in March 2014

    As a new type of nucleotide reverse transcriptase inhibitor, tenofovir dipivoxil has a sales volume of more than US $1 billion, which has surpassed that of adefovir dipivoxil

    The market has gradually surpassed the first-line drugs such as lamivudine and telbivudine

    Guangshengtang, which takes hepatitis B medicine as the core, whether tenofovir's future research and development can win the laurel will directly affect the company's future growth to a large extent

    The renewal of core varieties is imminent, and the market competition is intensifying

    The main varieties of guangshengtang include agandine (adefovir dipivoxil), heganding (lamivudine) and engendine (entecavir capsule)

    The total sales revenue from 2011 to 2013 accounted for 97.30%, 98.71% and 99.36% of the operating revenue of the same period respectively

    At present, there is not a kind of effective medicine which can remove hepatitis B virus quickly and directly in the world

    There are two kinds of effective antiviral drugs: nucleoside and interferon

    Big wisdom news agency learned from the industry that guangshengtang's main three drugs are nucleoside, which has the disadvantages of high drug resistance rate and rapid replacement of new and old drugs

    According to the time sequence of listing, in 1999, lamidine opened a new era of nucleoside analogues in the treatment of chronic hepatitis B in China

    Adefovir dipivoxil of GlaxoSmithKline and entecavir of Bristol Myers Squibb entered China successively at the end of 2005

    The change of sales proportion of gst-3 medicine can also clearly reflect the change of medicine "acting for talented people"

    From 2011 to 2013, the proportion of adefovir dipivoxil in the company's gross profit decreased from 84.9% to 48.71%, while the proportion of entecavir increased from the blank in 2011 to 31.19% in 2013

    For adefovir dipivoxil, pharmaceutical companies are ready to update it

    The senior of Shuanglu pharmaceutical industry once said that it will take 4-5 years for adefovir dipivoxil to develop its drug resistance, which has been considered as an antiviral drug with a long life cycle

    The future growth of the drug may only be 1-2 years, and it needs to be renewed

    For the life cycle of three main varieties, guangshengtang said, "there is no direct correlation between drug life cycle and drug resistance

    In addition, entecavir and tenofovir are low resistance drugs

    We actively explore but do not predict the future development of pharmaceutical science and technology

    In addition, it is worth noting that since 2010, guangshengtang has adopted the direct sales mode in Beijing and Shanghai

    In order to strive for customers to expand the market, it has adopted the sales policy of "goods before payment"

    From 2013, the company began to gradually develop direct selling mode in some areas of Zhejiang Province, and adopted the collection policy of "goods first, payment later"

    This is the company's extraordinary move to expand the national market, but also exposed the company's competitive disadvantage outside the base market of Fujian

    A Shenzhen drug agent said that for prescription drugs, the supplier is relatively strong, and there is little phenomenon of first delivery and then payment, especially for hepatitis B prescription drugs

    The reason is usually that the market competition is fierce and the supplier is in a weak position

    Industry insiders pointed out that the market competition of hepatitis B drugs is fierce

    Compared with domestic and foreign giants, such as GlaxoSmithKline, Novartis, Zhengda Tianqing and other brand pharmaceutical enterprises, the competitiveness of GST is not outstanding

    At present, its market share is also small

    In 2012, the company's sales accounted for only 4.13% of the market share of antiviral hepatitis B drugs in China
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.